Table 2.
FGFR gene alterations in GC.
| Method | n | Positive expression definition | % |
Relation to clinicopathological factors |
Relation to survival | Reference | |
|---|---|---|---|---|---|---|---|
| FGFR2 amplification | FISH | 961 | FGFR2/CEP-10 ratio ≥2 or FGFR2 gene clusters in ≥10% | 5.6 | N | Worse | [31] |
| FISH | 313 | FGFR2/CEP-10 ratio ≥2 or FGFR2 gene clusters | 4.5 | T, N, M, stage | Worse | [29] | |
| FISH | 171 | FGFR2/CEP-10 ratio ≥2 | 1.8 | ND | Worse | [28] | |
| FISH | 137 | FGFR2/CEP-10 ratio ≥2 | 7.3 | Undifferentiated type | Worse | [30] | |
| RT-PCR | 267 | FGFR2 >5 copies | 4.1 | NA | worse | [32] | |
| SNP microarray | 193 | GISTIC algorithm | 9.3 | NA | NA | [33] | |
| SNP microarray | 100 | GISTIC algorithm | 3.0 | ND | Not investigated | [34] | |
| FGFR4 SNIP | PCR-RFLP | 103 | Arg388 allele | 57 | NA | Worse | [36] |
| FGFR1 mutation | Whole-exome sequence | 138 | 2.2 | ND | ND | [37] |
FISH: fluorescence in situ hybridization; RT-PCR: reverse-transcription polymerase chain reaction; SNP: single nucleotide polymorphism; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism analysis; CEP: chromosome enumeration probe; GISTIC: the genomic identification of significant targets in cancer; T: tumor depth; N: lymph-node metastasis; M: distant metastasis; NA: not assisted; ND: not described.